Search Result

All Related Services Other Content

Solid Form Screening Our solid form screening technology applies to polymorph screening, salt screening and cocrystal screening. Our screening technology is to design various crystallization conditions according to the physicochemical properties of the target compound and factors affecting drug crystallization, to screen and discover the most comprehensive solid form for subsequent evaluation and development. Our proprietary solid form screening technology has been applied to over 1,500 different drug molecules and proven to be efficient and effective in screening and identifying the most optimal solid form for development.
Solid Form Developability Evaluation Solid form developability evaluation technology is to evaluate the developability of crystal forms, including polymorphs, salts and cocrystals obtained in the solid form screening experiments and analyze potential risks and challenges of development. Through years of technical accumulation, Crystal Pharmatech has formed a complete evaluation system for solid form developability.
Absolute Structure Determination Single crystal growth and structure determination technology are the main methods to determine the absolute configuration of drug molecules and identify the crystal forms absolutely. The single crystal culture and analysis technology firstly obtain high-quality crystals through a variety of experimental single crystal growth methods. The main single crystal growth methods include slow evaporation, gas-liquid infiltration, slow cooling and liquid surface diffusion.
Crystallization Process Development On the basis of in-depth research on the properties of the crystal form itself and the transformation relationship between crystal forms, Crystal Pharmatech's crystallization process development technology realizes the selection and control of the crystallization system, crystallization conditions and post-processing conditions, so as to obtain the target crystal form at the same time taking into account the API particle properties, yield and cost, etc.
Mol2Med™ Integrated Services Crystal Pharmatech are a specialized CRO/CDMO focused on Solid State Research, Pre-Formulation, Formulation Development and Manufacturing. Our strength is our focus and expertise in these specialties...
Improving the Manufacture of mRNA Biologics
Solid Form Landscape to Formulation Strategy: The Role of Computational Screening and Risk Assessment Unexpected polymorphs can upend formulation by shifting solubility, stability, and manufacturability.This webinar shows how in silico crystal structure prediction (CSP), paired with competing-form ris...
Determination and Control of Crystal Form in ASD Formulations: A Case Study on Everolimus Tablets Amorphous solid dispersion (ASD) is a formulation strategy in which a drug is molecularly dispersed in a suitable polymer matrix, forming an amorphous solid solution or suspension that can markedly en...
Presentation / Poster
A Significant Step Toward Greater Clarity in Polymorph Control for Innovative Drugs Suzhou, China – January 28, 2026 – A regulatory authority has released the world's first guideline dedicated specifically to polymorph research for innovative chemical drugs, providing a structu...
Meet Crystal Pharmatech at DCAT Week 2026 Crystal Pharmatech is returning to DCAT Week with expanded capabilities. We have grown into a global CDMO with 300+ scientists across the US, Canada, and China, having supported over 2,000 NCEs to dat...
Home Crystal Pharmatech's Mol2Med™ First-Time-Right approach guarantees a robust API form and a scalable manufacturing process, culminating in a First-Time-Right formulation for Phase I. Streamlining the transition to future clinical studies upon Phase I success, this innovative approach sets the foundation for optimized drug development and success beyond.